Compare · PEPG vs TRDA

PEPG vs TRDA

Side-by-side comparison of PepGen Inc. (PEPG) and Entrada Therapeutics Inc. (TRDA): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both PEPG and TRDA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • PEPG is the larger of the two at $370.4M, about 2.0x TRDA ($181.7M).
  • Over the past year, PEPG is down 22.8% and TRDA is down 49.3% - PEPG leads by 26.4 points.
  • PEPG has been more active in the news (12 items in the past 4 weeks vs 4 for TRDA).
  • TRDA has more recent analyst coverage (10 ratings vs 6 for PEPG).
PerformancePEPG-22.84%TRDA-49.29%
2025-11-20+0.00%2026-11-19
MetricPEPGTRDA
Company
PepGen Inc.
Entrada Therapeutics Inc.
Price
-
-
Market cap
$370.4M
$181.7M
1M return
+44.14%
+0.11%
1Y return
-22.84%
-49.29%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
2022
2021
News (4w)
12
4
Recent ratings
6
10
PEPG

PepGen Inc.

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

TRDA

Entrada Therapeutics Inc.

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy. It also engages in the development of EEV-PMO for the treatment of Duchenne myotonic dystrophy type 1 (DM1). The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Latest PEPG

Latest TRDA